You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEtorphine
Accession NumberDB01497
TypeSmall Molecule
GroupsIllicit, Vet Approved
DescriptionA narcotic analgesic morphinan used as a sedative in veterinary practice. In Hong Kong, Etorphine is regulated under Schedule 1 of Hong Kong's Chapter 134 Dangerous Drugs Ordinance. It can only be used legally by health professionals and for university research purposes. The substance can be given by pharmacists under a prescription. In the US, Etorphine is listed as a Schedule I drug, although Etorphine hydrochloride is classified as Schedule II.
Structure
Thumb
Synonyms
Etorphinum
External Identifiers
  • DEA No. 9056
  • M99
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Etorphine Hydrochloride
Thumb
  • InChI Key: JNHPUZURWFYYHW-DTUSRQQPSA-N
  • Monoisotopic Mass: 447.217636288
  • Average Mass: 447.995
DBSALT000825
Categories
UNII42M2Y6NU9O
CAS number14521-96-1
WeightAverage: 411.5338
Monoisotopic: 411.240958549
Chemical FormulaC25H33NO4
InChI KeyInChIKey=CAHCBJPUTCKATP-HBDRVVKHSA-N
InChI
InChI=1S/C25H33NO4/c1-5-8-22(2,28)17-14-23-9-10-25(17,29-4)21-24(23)11-12-26(3)18(23)13-15-6-7-16(27)20(30-21)19(15)24/h6-7,9-10,17-18,21,27-28H,5,8,11-14H2,1-4H3/t17?,18-,21?,22?,23-,24+,25?/m1/s1
IUPAC Name
(1R,2R,6S)-19-(2-hydroxypentan-2-yl)-15-methoxy-3-methyl-13-oxa-3-azahexacyclo[13.2.2.1²,⁸.0¹,⁶.0⁶,¹⁴.0⁷,¹²]icosa-7,9,11,16-tetraen-11-ol
SMILES
[H][C@]12CC3=C4C(OC5[C@@]4(CCN1C)[C@]21CC(C(C)(O)CCC)C5(OC)C=C1)=C(O)C=C3
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassMorphinans
Sub ClassNot Available
Direct ParentMorphinans
Alternative Parents
Substituents
  • Morphinan
  • Benzylisoquinoline
  • Phenanthrene
  • Tetralin
  • Azaspirodecane
  • Benzofuran
  • Aralkylamine
  • Alkyl aryl ether
  • Benzenoid
  • Piperidine
  • Tertiary alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationNot Available
PharmacodynamicsEtorphine is a synthetic cousin of morphine and 40,000 times more powerful. It can be produced from thebaine. It is most often used to immobilize elephants and other large mammals. Etorphine is only available legally for veterinary use and is strictly governed by law.
Mechanism of actionEtorphine is an agonist at mu, delta, and kappa opioid receptors. It also has a weak affinity for the ORL1 nociceptin/orphanin FQ receptor.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9954
Blood Brain Barrier+0.9708
Caco-2 permeable+0.7322
P-glycoprotein substrateSubstrate0.9173
P-glycoprotein inhibitor IInhibitor0.7399
P-glycoprotein inhibitor IINon-inhibitor0.7779
Renal organic cation transporterNon-inhibitor0.6479
CYP450 2C9 substrateNon-substrate0.8713
CYP450 2D6 substrateSubstrate0.7349
CYP450 3A4 substrateSubstrate0.7858
CYP450 1A2 substrateNon-inhibitor0.9392
CYP450 2C9 inhibitorNon-inhibitor0.8992
CYP450 2D6 inhibitorNon-inhibitor0.6197
CYP450 2C19 inhibitorNon-inhibitor0.8553
CYP450 3A4 inhibitorNon-inhibitor0.8272
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9294
Ames testNon AMES toxic0.7862
CarcinogenicityNon-carcinogens0.9372
BiodegradationNot ready biodegradable0.9973
Rat acute toxicity3.2955 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8072
hERG inhibition (predictor II)Non-inhibitor0.7219
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point214-217 °CPhysProp
logP2.79SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility0.112 mg/mLALOGPS
logP3.29ALOGPS
logP2.47ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)7.48ChemAxon
pKa (Strongest Basic)11.72ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area62.16 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity116.51 m3·mol-1ChemAxon
Polarizability45.55 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Etorphine.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Etorphine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Etorphine is combined with 7-Nitroindazole.
AcepromazineAcepromazine may increase the hypotensive activities of Etorphine.
AcepromazineThe risk or severity of adverse effects can be increased when Etorphine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Etorphine is combined with Aceprometazine.
AcetazolamideThe risk or severity of adverse effects can be increased when Etorphine is combined with Acetazolamide.
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Etorphine.
adipiplonThe risk or severity of adverse effects can be increased when Etorphine is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Etorphine is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Etorphine is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Etorphine.
AlimemazineAlimemazine may increase the hypotensive activities of Etorphine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Etorphine is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Etorphine.
AlvimopanThe risk or severity of adverse effects can be increased when Etorphine is combined with Alvimopan.
AmilorideThe risk or severity of adverse effects can be increased when Etorphine is combined with Amiloride.
AmisulprideThe risk or severity of adverse effects can be increased when Etorphine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Etorphine is combined with Amitriptyline.
Ammonium chlorideAmmonium chloride may increase the excretion rate of Etorphine which could result in a higher serum level.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Etorphine.
AmoxapineEtorphine may increase the serotonergic activities of Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Etorphine.
AmperozideThe risk or severity of adverse effects can be increased when Etorphine is combined with Amperozide.
AmphetamineAmphetamine may increase the analgesic activities of Etorphine.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Etorphine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Etorphine.
ArticaineThe risk or severity of adverse effects can be increased when Etorphine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Etorphine is combined with Asenapine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Etorphine.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Etorphine.
AzaperoneThe risk or severity of adverse effects can be increased when Etorphine is combined with Azaperone.
AzelastineEtorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Etorphine.
AzosemideThe risk or severity of adverse effects can be increased when Etorphine is combined with Azosemide.
BaclofenThe risk or severity of adverse effects can be increased when Etorphine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Etorphine.
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Etorphine.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Etorphine is combined with Bendroflumethiazide.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Etorphine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Etorphine.
BenzphetamineBenzphetamine may increase the analgesic activities of Etorphine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Etorphine is combined with Benzyl alcohol.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Etorphine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Etorphine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Etorphine.
BrimonidineThe risk or severity of adverse effects can be increased when Etorphine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Etorphine is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Etorphine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Etorphine is combined with Brotizolam.
BumetanideThe risk or severity of adverse effects can be increased when Etorphine is combined with Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Etorphine.
BuprenorphineBuprenorphine may decrease the analgesic activities of Etorphine.
BuprenorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Etorphine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Etorphine.
ButacaineThe risk or severity of adverse effects can be increased when Etorphine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Etorphine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Etorphine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Etorphine.
ButorphanolButorphanol may decrease the analgesic activities of Etorphine.
ButorphanolThe risk or severity of adverse effects can be increased when Etorphine is combined with Butorphanol.
Canrenoic acidThe risk or severity of adverse effects can be increased when Etorphine is combined with Canrenoic acid.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Etorphine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Etorphine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Etorphine is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Etorphine is combined with Carisoprodol.
CetirizineThe risk or severity of adverse effects can be increased when Etorphine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Etorphine is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Etorphine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Etorphine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Etorphine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Etorphine is combined with Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Etorphine is combined with Chlorphenamine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Etorphine.
ChlorphentermineChlorphentermine may increase the analgesic activities of Etorphine.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Etorphine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Etorphine is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Etorphine.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Etorphine is combined with Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Etorphine is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Etorphine.
CitalopramEtorphine may increase the serotonergic activities of Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Etorphine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Etorphine is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Etorphine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Etorphine is combined with clomethiazole.
ClomipramineEtorphine may increase the serotonergic activities of Clomipramine.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Etorphine.
ClonazepamThe risk or severity of adverse effects can be increased when Etorphine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Etorphine is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Etorphine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Etorphine.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Etorphine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Etorphine.
ConivaptanThe risk or severity of adverse effects can be increased when Etorphine is combined with Conivaptan.
CyclizineThe risk or severity of adverse effects can be increased when Etorphine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Etorphine.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Etorphine.
CyclothiazideThe risk or severity of adverse effects can be increased when Etorphine is combined with Cyclothiazide.
CyproheptadineThe risk or severity of adverse effects can be increased when Etorphine is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Etorphine is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Etorphine.
DapoxetineEtorphine may increase the serotonergic activities of Dapoxetine.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Etorphine.
deramciclaneThe risk or severity of adverse effects can be increased when Etorphine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Etorphine.
DesipramineThe risk or severity of adverse effects can be increased when Etorphine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Etorphine.
DesmopressinThe risk or severity of adverse effects can be increased when Etorphine is combined with Desmopressin.
DetomidineThe risk or severity of adverse effects can be increased when Etorphine is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Etorphine is combined with Dexbrompheniramine.
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Etorphine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Etorphine.
DextroamphetamineDextroamphetamine may increase the analgesic activities of Etorphine.
DextromoramideThe risk or severity of adverse effects can be increased when Etorphine is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Etorphine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Etorphine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Etorphine.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Etorphine.
DifenoxinThe risk or severity of adverse effects can be increased when Etorphine is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Etorphine is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Etorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Dihydromorphine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Etorphine is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Etorphine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Etorphine.
DoramectinThe risk or severity of adverse effects can be increased when Etorphine is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Etorphine is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Etorphine.
DoxylamineThe risk or severity of adverse effects can be increased when Etorphine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Etorphine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Etorphine.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Etorphine.
DrospirenoneThe risk or severity of adverse effects can be increased when Etorphine is combined with Drospirenone.
DrotebanolThe risk or severity of adverse effects can be increased when Etorphine is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Etorphine.
EcgonineThe risk or severity of adverse effects can be increased when Etorphine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Etorphine is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Etorphine is combined with Efavirenz.
EfonidipineThe risk or severity of adverse effects can be increased when Etorphine is combined with Efonidipine.
EluxadolineEtorphine may increase the constipating activities of Eluxadoline.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Etorphine.
EntacaponeThe risk or severity of adverse effects can be increased when Etorphine is combined with Entacapone.
EplerenoneThe risk or severity of adverse effects can be increased when Etorphine is combined with Eplerenone.
EscitalopramEtorphine may increase the serotonergic activities of Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Etorphine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Etorphine.
Etacrynic acidThe risk or severity of adverse effects can be increased when Etorphine is combined with Etacrynic acid.
EthanolEtorphine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Etorphine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etorphine.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Etorphine.
EthosuximideThe risk or severity of adverse effects can be increased when Etorphine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Etorphine is combined with Ethotoin.
EthoxzolamideThe risk or severity of adverse effects can be increased when Etorphine is combined with Ethoxzolamide.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Etorphine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Etorphine is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Etorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Etorphine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Etorphine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Etorphine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Etorphine.
EtoperidoneEtorphine may increase the serotonergic activities of Etoperidone.
EzogabineThe risk or severity of adverse effects can be increased when Etorphine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Etorphine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Etorphine.
FenfluramineEtorphine may increase the serotonergic activities of Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Etorphine.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Etorphine.
FexofenadineThe risk or severity of adverse effects can be increased when Etorphine is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Etorphine is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Etorphine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Etorphine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Etorphine is combined with Flunitrazepam.
FluoxetineEtorphine may increase the serotonergic activities of Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Etorphine.
FluphenazineFluphenazine may increase the hypotensive activities of Etorphine.
FluphenazineThe risk or severity of adverse effects can be increased when Etorphine is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Etorphine.
FluspirileneThe risk or severity of adverse effects can be increased when Etorphine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Etorphine is combined with Fluticasone Propionate.
FluvoxamineEtorphine may increase the serotonergic activities of Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Etorphine.
FosphenytoinThe risk or severity of adverse effects can be increased when Etorphine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Etorphine is combined with Fospropofol.
FurosemideThe risk or severity of adverse effects can be increased when Etorphine is combined with Furosemide.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Etorphine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Etorphine is combined with gabapentin enacarbil.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Etorphine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Etorphine.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Etorphine.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Etorphine.
GuanfacineThe risk or severity of adverse effects can be increased when Etorphine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Etorphine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Etorphine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Etorphine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Etorphine.
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Etorphine.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Etorphine.
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Etorphine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Etorphine is combined with Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Etorphine.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Etorphine is combined with Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Etorphine.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Etorphine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Etorphine.
HydroxyzineThe risk or severity of adverse effects can be increased when Etorphine is combined with Hydroxyzine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Etorphine.
IloperidoneThe risk or severity of adverse effects can be increased when Etorphine is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Etorphine is combined with Imipramine.
IndalpineEtorphine may increase the serotonergic activities of Indalpine.
IndapamideThe risk or severity of adverse effects can be increased when Etorphine is combined with Indapamide.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Etorphine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Etorphine.
IsosorbideThe risk or severity of adverse effects can be increased when Etorphine is combined with Isosorbide.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Etorphine.
KetazolamThe risk or severity of adverse effects can be increased when Etorphine is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Etorphine is combined with Ketobemidone.
KW-3902The risk or severity of adverse effects can be increased when Etorphine is combined with KW-3902.
LamotrigineThe risk or severity of adverse effects can be increased when Etorphine is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Etorphine is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Etorphine.
LevocabastineThe risk or severity of adverse effects can be increased when Etorphine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Etorphine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Etorphine is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Etorphine.
LevomilnacipranEtorphine may increase the serotonergic activities of Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Etorphine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Etorphine.
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Etorphine.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Etorphine.
LofentanilThe risk or severity of adverse effects can be increased when Etorphine is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Etorphine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Etorphine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Etorphine.
Lu AA21004Etorphine may increase the serotonergic activities of Lu AA21004.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Etorphine.
LurasidoneThe risk or severity of adverse effects can be increased when Etorphine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Etorphine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Etorphine is combined with Magnesium Sulfate.
MannitolThe risk or severity of adverse effects can be increased when Etorphine is combined with Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Etorphine is combined with Maprotiline.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Etorphine.
MeclizineThe risk or severity of adverse effects can be increased when Etorphine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Etorphine is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Etorphine.
MelperoneThe risk or severity of adverse effects can be increased when Etorphine is combined with Melperone.
MephentermineMephentermine may increase the analgesic activities of Etorphine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Etorphine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Etorphine.
MersalylThe risk or severity of adverse effects can be increased when Etorphine is combined with Mersalyl.
MesoridazineMesoridazine may increase the hypotensive activities of Etorphine.
MesoridazineThe risk or severity of adverse effects can be increased when Etorphine is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Etorphine is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Etorphine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Etorphine.
MethamphetamineMethamphetamine may increase the analgesic activities of Etorphine.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Etorphine.
MethapyrileneThe risk or severity of adverse effects can be increased when Etorphine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Etorphine is combined with Methaqualone.
MethazolamideThe risk or severity of adverse effects can be increased when Etorphine is combined with Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Etorphine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Etorphine.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Etorphine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Etorphine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Etorphine.
MethsuximideThe risk or severity of adverse effects can be increased when Etorphine is combined with Methsuximide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Etorphine is combined with Methyclothiazide.
Methylene blueMethylene blue may increase the hypotensive activities of Etorphine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Etorphine.
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Etorphine.
MetolazoneThe risk or severity of adverse effects can be increased when Etorphine is combined with Metolazone.
MetyrosineEtorphine may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Etorphine.
MilnacipranEtorphine may increase the serotonergic activities of Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Etorphine.
MirtazapineEtorphine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Etorphine.
MolindoneThe risk or severity of adverse effects can be increased when Etorphine is combined with Molindone.
MoricizineMoricizine may increase the hypotensive activities of Etorphine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Etorphine.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Etorphine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Etorphine.
NabiloneThe risk or severity of adverse effects can be increased when Etorphine is combined with Nabilone.
NalbuphineNalbuphine may decrease the analgesic activities of Etorphine.
NalbuphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Nalbuphine.
NaltrexoneThe therapeutic efficacy of Etorphine can be decreased when used in combination with Naltrexone.
NitrazepamThe risk or severity of adverse effects can be increased when Etorphine is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Etorphine is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Etorphine is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Etorphine is combined with Nortriptyline.
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Etorphine.
OlanzapineEtorphine may increase the serotonergic activities of Olanzapine.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Etorphine.
OlopatadineThe risk or severity of adverse effects can be increased when Etorphine is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Etorphine.
OpiumThe risk or severity of adverse effects can be increased when Etorphine is combined with Opium.
OrphenadrineEtorphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Etorphine.
OsanetantThe risk or severity of adverse effects can be increased when Etorphine is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Etorphine.
OxprenololThe risk or severity of adverse effects can be increased when Etorphine is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Etorphine.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Etorphine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Etorphine.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Etorphine.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Etorphine.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Etorphine.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Etorphine.
ParaldehydeEtorphine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Etorphine.
ParoxetineEtorphine may increase the serotonergic activities of Paroxetine.
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Etorphine.
PentazocinePentazocine may decrease the analgesic activities of Etorphine.
PentazocineThe risk or severity of adverse effects can be increased when Etorphine is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Etorphine.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Etorphine.
PerampanelThe risk or severity of adverse effects can be increased when Etorphine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Etorphine is combined with Perospirone.
PerphenazinePerphenazine may increase the hypotensive activities of Etorphine.
PerphenazineThe risk or severity of adverse effects can be increased when Etorphine is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Etorphine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Etorphine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Etorphine is combined with Phenoxyethanol.
PhenterminePhentermine may increase the analgesic activities of Etorphine.
PhenytoinThe risk or severity of adverse effects can be increased when Etorphine is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Etorphine.
PipamperoneThe risk or severity of adverse effects can be increased when Etorphine is combined with Pipamperone.
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Etorphine.
PipotiazineThe risk or severity of adverse effects can be increased when Etorphine is combined with Pipotiazine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Etorphine.
PiretanideThe risk or severity of adverse effects can be increased when Etorphine is combined with Piretanide.
PizotifenThe risk or severity of adverse effects can be increased when Etorphine is combined with Pizotifen.
PolythiazideThe risk or severity of adverse effects can be increased when Etorphine is combined with Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Etorphine is combined with Pomalidomide.
PotassiumThe risk or severity of adverse effects can be increased when Etorphine is combined with Potassium.
Potassium CitrateThe risk or severity of adverse effects can be increased when Etorphine is combined with Potassium Citrate.
PramipexoleEtorphine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Etorphine is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Etorphine is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Etorphine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Etorphine.
PrimidoneThe risk or severity of adverse effects can be increased when Etorphine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Etorphine.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Etorphine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Etorphine is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Etorphine.
PromazinePromazine may increase the hypotensive activities of Etorphine.
PromazineThe risk or severity of adverse effects can be increased when Etorphine is combined with Promazine.
PromethazinePromethazine may increase the hypotensive activities of Etorphine.
PromethazineThe risk or severity of adverse effects can be increased when Etorphine is combined with Promethazine.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Etorphine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Etorphine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Etorphine.
PropoxycaineThe risk or severity of adverse effects can be increased when Etorphine is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Etorphine is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Etorphine is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Etorphine is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Etorphine.
QuinethazoneThe risk or severity of adverse effects can be increased when Etorphine is combined with Quinethazone.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Etorphine.
RamelteonThe risk or severity of adverse effects can be increased when Etorphine is combined with Ramelteon.
RamosetronEtorphine may increase the constipating activities of Ramosetron.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Etorphine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Etorphine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Etorphine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Etorphine.
RomifidineThe risk or severity of adverse effects can be increased when Etorphine is combined with Romifidine.
RopiniroleEtorphine may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Etorphine.
RotigotineEtorphine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Etorphine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Etorphine is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Etorphine.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Etorphine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Etorphine.
SertindoleThe risk or severity of adverse effects can be increased when Etorphine is combined with Sertindole.
SertralineEtorphine may increase the serotonergic activities of Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Etorphine.
Sodium oxybateThe risk or severity of adverse effects can be increased when Etorphine is combined with Sodium oxybate.
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Etorphine.
SpironolactoneThe risk or severity of adverse effects can be increased when Etorphine is combined with Spironolactone.
StiripentolThe risk or severity of adverse effects can be increased when Etorphine is combined with Stiripentol.
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Etorphine.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Etorphine.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Etorphine.
SuvorexantThe risk or severity of adverse effects can be increased when Etorphine is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Etorphine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Etorphine is combined with Tasimelteon.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Etorphine.
TetrabenazineThe risk or severity of adverse effects can be increased when Etorphine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Etorphine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Etorphine is combined with Tetrodotoxin.
ThalidomideEtorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Etorphine.
TheobromineThe risk or severity of adverse effects can be increased when Etorphine is combined with Theobromine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Etorphine.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Etorphine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Etorphine.
ThioridazineThioridazine may increase the hypotensive activities of Etorphine.
ThioridazineThe risk or severity of adverse effects can be increased when Etorphine is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Etorphine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Etorphine is combined with Tiagabine.
TicrynafenThe risk or severity of adverse effects can be increased when Etorphine is combined with Ticrynafen.
TiletamineThe risk or severity of adverse effects can be increased when Etorphine is combined with Tiletamine.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Etorphine.
TizanidineThe risk or severity of adverse effects can be increased when Etorphine is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Etorphine is combined with Tolcapone.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Etorphine.
TolvaptanThe risk or severity of adverse effects can be increased when Etorphine is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Etorphine is combined with Topiramate.
TorasemideThe risk or severity of adverse effects can be increased when Etorphine is combined with Torasemide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Etorphine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Etorphine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Etorphine.
TrazodoneEtorphine may increase the serotonergic activities of Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Etorphine.
TriamtereneThe risk or severity of adverse effects can be increased when Etorphine is combined with Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Etorphine.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Etorphine is combined with Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Etorphine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Etorphine is combined with Trifluoperazine.
TriflupromazineTriflupromazine may increase the hypotensive activities of Etorphine.
TriflupromazineThe risk or severity of adverse effects can be increased when Etorphine is combined with Triflupromazine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Etorphine.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Etorphine.
TrimipramineThe risk or severity of adverse effects can be increased when Etorphine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Etorphine is combined with Triprolidine.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Etorphine.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Etorphine.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Etorphine.
UlaritideThe risk or severity of adverse effects can be increased when Etorphine is combined with Ularitide.
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Etorphine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Etorphine.
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Etorphine.
VigabatrinThe risk or severity of adverse effects can be increased when Etorphine is combined with Vigabatrin.
VilazodoneEtorphine may increase the serotonergic activities of Vilazodone.
VortioxetineEtorphine may increase the serotonergic activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Etorphine.
XylazineThe risk or severity of adverse effects can be increased when Etorphine is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Etorphine.
ZiconotideThe risk or severity of adverse effects can be increased when Etorphine is combined with Ziconotide.
ZimelidineEtorphine may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Etorphine.
ZolazepamThe risk or severity of adverse effects can be increased when Etorphine is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Etorphine.
ZonisamideThe risk or severity of adverse effects can be increased when Etorphine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Etorphine.
ZotepineThe risk or severity of adverse effects can be increased when Etorphine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Etorphine is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Duttaroy A, Yoburn BC: In vivo regulation of mu-opioid receptor density and gene expression in CXBK and outbred Swiss Webster mice. Synapse. 2000 Aug;37(2):118-24. [PubMed:10881033 ]
  2. Melone M, Brecha NC, Sternini C, Evans C, Conti F: Etorphine increases the number of mu-opioid receptor-positive cells in the cerebral cortex. Neuroscience. 2000;100(3):439-43. [PubMed:11098106 ]
  3. Stafford K, Gomes AB, Shen J, Yoburn BC: mu-Opioid receptor downregulation contributes to opioid tolerance in vivo. Pharmacol Biochem Behav. 2001 May-Jun;69(1-2):233-7. [PubMed:11420091 ]
  4. Gomes BA, Shen J, Stafford K, Patel M, Yoburn BC: Mu-opioid receptor down-regulation and tolerance are not equally dependent upon G-protein signaling. Pharmacol Biochem Behav. 2002 May;72(1-2):273-8. [PubMed:11900797 ]
  5. Patel MB, Patel CN, Rajashekara V, Yoburn BC: Opioid agonists differentially regulate mu-opioid receptors and trafficking proteins in vivo. Mol Pharmacol. 2002 Dec;62(6):1464-70. [PubMed:12435815 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Li JG, Benovic JL, Liu-Chen LY: Mechanisms of agonist-induced down-regulation of the human kappa-opioid receptor: internalization is required for down-regulation. Mol Pharmacol. 2000 Oct;58(4):795-801. [PubMed:10999950 ]
  2. Li JG, Zhang F, Jin XL, Liu-Chen LY: Differential regulation of the human kappa opioid receptor by agonists: etorphine and levorphanol reduced dynorphin A- and U50,488H-induced internalization and phosphorylation. J Pharmacol Exp Ther. 2003 May;305(2):531-40. Epub 2003 Jan 24. [PubMed:12606694 ]
  3. Marie N, Lecoq I, Jauzac P, Allouche S: Differential sorting of human delta-opioid receptors after internalization by peptide and alkaloid agonists. J Biol Chem. 2003 Jun 20;278(25):22795-804. Epub 2003 Apr 2. [PubMed:12672796 ]
  4. Sumner BE, Douglas AJ, Russell JA: Pregnancy alters the density of opioid binding sites in the supraoptic nucleus and posterior pituitary gland of rats. Neurosci Lett. 1992 Mar 30;137(2):216-20. [PubMed:1316589 ]
  5. Tao PL, Tsai CL, Chang LR, Loh HH: Chronic effect of [D-Pen2,D-Pen5]enkephalin on rat brain opioid receptors. Eur J Pharmacol. 1991 Aug 29;201(2-3):209-14. [PubMed:1665782 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Niwa M, al-Essa LY, Ohta S, Kohno K, Nozaki M, Tsurumi K, Iwamura T, Kataoka T: Opioid receptor interaction and adenylyl cyclase inhibition of dihydroetorphine: direct comparison with etorphine. Life Sci. 1995;56(21):PL395-400. [PubMed:7739347 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Niwa M, al-Essa LY, Ohta S, Kohno K, Nozaki M, Tsurumi K, Iwamura T, Kataoka T: Opioid receptor interaction and adenylyl cyclase inhibition of dihydroetorphine: direct comparison with etorphine. Life Sci. 1995;56(21):PL395-400. [PubMed:7739347 ]
  2. Wannemacher KM, Yadav PN, Howells RD: A select set of opioid ligands induce up-regulation by promoting the maturation and stability of the rat kappa-opioid receptor in human embryonic kidney 293 cells. J Pharmacol Exp Ther. 2007 Nov;323(2):614-25. Epub 2007 Aug 24. [PubMed:17720886 ]
  3. Gharagozlou P, Hashemi E, DeLorey TM, Clark JD, Lameh J: Pharmacological profiles of opioid ligands at kappa opioid receptors. BMC Pharmacol. 2006 Jan 25;6:3. [PubMed:16433932 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Nociceptin receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for the endogenous neuropeptide nociceptin. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling via G proteins mediates inhibition of adenylate cyclase activity and calcium channel activity. Arrestins mod...
Gene Name:
OPRL1
Uniprot ID:
P41146
Molecular Weight:
40692.775 Da
References
  1. Hawkinson JE, Acosta-Burruel M, Espitia SA: Opioid activity profiles indicate similarities between the nociceptin/orphanin FQ and opioid receptors. Eur J Pharmacol. 2000 Feb 18;389(2-3):107-14. [PubMed:10688973 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
E3 ubiquitin ligase involved in the retrotranslocation and turnover of membrane and secretory proteins from the ER through a set of processes named ER-associated degradation (ERAD). This process acts on misfolded proteins as well as in the regulated degradation of correctly folded proteins. Enhances ionizing radiation-induced p53/TP53 stability and apoptosis via ubiquitinating MDM2 and AKT1 and...
Gene Name:
TRIM13
Uniprot ID:
O60858
Molecular Weight:
46987.08 Da
References
  1. Maneckjee R, Archer S, Zukin RS: Characterization of a polyclonal antibody to the mu opioid receptor. J Neuroimmunol. 1988 Feb;17(3):199-208. [PubMed:2828423 ]
  2. Stojilkovic SS, Dufau ML, Catt KJ: Opiate receptor subtypes in the rat hypothalamus and neurointermediate lobe. Endocrinology. 1987 Jul;121(1):384-94. [PubMed:3036471 ]
  3. Pesce G, Lang MA, Russell JT, Rodbard D, Gainer H: Characterization of kappa opioid receptors in neurosecretosomes from bovine posterior pituitary. J Neurochem. 1987 Aug;49(2):421-7. [PubMed:3037028 ]
  4. Pfeiffer A, Herz A: Discrimination of three opiate receptor binding sites with the use of a computerized curve-fitting technique. Mol Pharmacol. 1982 Mar;21(2):266-71. [PubMed:6124875 ]
  5. Audigier Y, Mazarguil H, Gout R, Cros J: Structure-activity relationships of enkephalin analogs at opiate and enkephalin receptors: correlation with analgesia. Eur J Pharmacol. 1980 Apr 11;63(1):35-46. [PubMed:6247160 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Type 4 melanocortin receptor binding
Specific Function:
ACTH stimulates the adrenal glands to release cortisol.MSH (melanocyte-stimulating hormone) increases the pigmentation of skin by increasing melanin production in melanocytes.Beta-endorphin and Met-enkephalin are endogenous opiates.
Gene Name:
POMC
Uniprot ID:
P01189
Molecular Weight:
29423.72 Da
References
  1. Sanchez-Blazquez P, Garzon J: Further characterization of alpha N-acetyl beta-endorphin-(1-31) regulatory activity, I: Effect on opioid- and alpha 2-mediated supraspinal antinociception in mice. Life Sci. 1992;50(26):2083-97. [PubMed:1318989 ]
  2. Xu JY, Fujimoto JM, Tseng LF: Involvement of supraspinal epsilon and mu opioid receptors in inhibition of the tail-flick response induced by etorphine in the mouse. J Pharmacol Exp Ther. 1992 Oct;263(1):246-52. [PubMed:1328609 ]
  3. Nicolas P, Li CH: Beta-endorphin-(1-27) is a naturally occurring antagonist to etorphine-induced analgesia. Proc Natl Acad Sci U S A. 1985 May;82(10):3178-81. [PubMed:2987913 ]
  4. Dum J, Gramsch C, Herz A: Activation of hypothalamic beta-endorphin pools by reward induced by highly palatable food. Pharmacol Biochem Behav. 1983 Mar;18(3):443-7. [PubMed:6132412 ]
  5. Lemaire S, Livett B, Tseng R, Mercier P, Lemaire I: Studies on the inhibitory action of opiate compounds in isolated bovine adrenal chromaffin cells: noninvolvement of stereospecific opiate binding sites. J Neurochem. 1981 Mar;36(3):886-92. [PubMed:6259293 ]
Comments
comments powered by Disqus
Drug created on July 31, 2007 07:09 / Updated on August 17, 2016 12:23